Company Filing History:
Years Active: 2016
Title: Erik Krogh-Jespersen: Innovator in Pharmaceutical Chemistry
Introduction
Erik Krogh-Jespersen is a notable inventor based in Palo Alto, CA. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target immune disorders. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.
Latest Patents
Erik holds a patent for "N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease." This invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, and methods for inhibiting RORγ activity. It also focuses on reducing the amount of IL-17 in a subject and treating immune and inflammatory disorders using these compounds. This patent highlights Erik's commitment to addressing critical health issues through innovative solutions.
Career Highlights
Erik is currently associated with Lycera Corporation, where he continues to work on groundbreaking research and development in the pharmaceutical sector. His role at Lycera allows him to collaborate with other talented professionals and contribute to the advancement of therapeutic options for patients.
Collaborations
Some of Erik's notable coworkers include Gary D. Glick and Peter Laurence Toogood. Their collaboration fosters a dynamic environment for innovation and research, enhancing the potential for impactful discoveries in the field of medicine.
Conclusion
Erik Krogh-Jespersen is a distinguished inventor whose work in pharmaceutical chemistry is paving the way for new treatments for immune disorders. His patent and ongoing research at Lycera Corporation exemplify his dedication to improving health outcomes through innovative science.